MedTrace Logo

Safety and Efficacy of NK510 to Treat Osteosarcoma and Soft Tissue Sarcoma

NCT06117878 · Status: RECRUITING · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2023-11-07

No results posted yet for this study

Summary

This study will evaluate the safety and efficacy of NK510 in the treatment of Osteosarcoma and Soft Tissue Sarcoma.NK510 will be administered by intravenous injection. The safety and efficacy of this treatment will be evaluated.

Conditions

Interventions

DRUG

NK510

NK510 will be administered through intravenous infusion.once a week，for a total of six times.

DRUG

NK510

NK510 will be administered through intravenous infusion.Twice infusions on week 1,week 3,week 5 respectively.

Sponsors & Collaborators

  • Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

    collaborator OTHER

  • Base Therapeutics (Shanghai) Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Yingqi Hua, phD · Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
10 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-09-01
Primary Completion
2024-09-01
Completion
2024-09-01

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06117878 on ClinicalTrials.gov